Physician profile
Hani Ahmad
NPI 1790711604
$4,598.49
in general payments reported to CMS, 2019-2025
28 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $511 · 2021: $433 · 2022: $444 · 2023: $583 · 2024: $771 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,793 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.53 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $970.06 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $541.62 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $502.97 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $492.50 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $296.09 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $203.39 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $188.52 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $171.37 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $151.43 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $130.53 | 2023-2025 | Auvelity |
| Indivior INC. | $125.68 | 2019-2024 | Perseris, Sublocade |
| Idorsia Pharmaceuticals US INC | $107.10 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.20 | 2022-2024 | Caplyta |
| Biogen, INC. | $90.60 | 2024 | |
| Abbvie INC. | $82.33 | 2023-2025 | Vraylar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $61.83 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.37 | 2019-2023 | Trintellix |
| Tris Pharma INC | $54.03 | 2022-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $48.02 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Gilead Sciences, INC. | $37.49 | 2023-2024 | Epclusa |
| Corium, LLC | $37.16 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $32.58 | 2022-2024 | Xelstrym |
| Shire North American Group INC | $32.23 | 2019 | |
| Brainsway USA INC | $23.90 | 2023 | |
| Neos Therapeutics, LP | $20.87 | 2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $17.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.74 | 2019 | |
| Adlon Therapeutics L.P. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.